Leerink Partners analyst Andrew Berens maintained a Buy rating on AstraZeneca (AZN – Research Report) on February 10 and set a price target of $85.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Andrew Berens’s rating is based on AstraZeneca’s strong financial performance and future growth projections. The company reported robust product revenues that surpassed consensus estimates, particularly in their oncology portfolio which saw significant beats in multiple products. This positive performance is complemented by AstraZeneca’s 2025 financial guidance, which forecasts a high single-digit increase in total revenue and a low double-digit rise in core EPS, indicating a promising growth trajectory.
Furthermore, AstraZeneca’s management provided clarity on the ongoing investigations in China, which, despite the challenges, are expected to result in a smaller financial impact than initially feared. This development alleviates some investor concerns. Additionally, despite a slight revenue decline in China during the fourth quarter due to seasonal factors, the company’s overall revenue in the region increased significantly over the year. These factors collectively contribute to a favorable outlook for AstraZeneca’s stock.
In another report released on February 10, Goldman Sachs also maintained a Buy rating on the stock with a $97.00 price target.